POPULARITY
2 episodes with Matthew S Davids
2 episodes with Matthew S Davids
2 episodes with Matthew S Davids
2 episodes with Matthew S Davids
3 episodes with Matthew S Davids
2 episodes with Matthew S Davids
2 episodes with Matthew S Davids
Featuring perspectives from Dr Matthew S Davids, including the following topics: Introduction: Is Chronic Lymphocytic Leukemia (CLL) the New Chronic Myeloid Leukemia? Cases We Didn't Hear About Last Week (0:00) Case: A man in his early 70s with IGHV-unmutated CLL (trisomy 12, del[17p]) receives ibrutinib for several years and is switched to acalabrutinib to lower the risk of cardiotoxicity — Warren S Brenner, MD (16:39) Case: A man in his mid 70s with relapsed atypical del(17p) CLL who previously received ibrutinib receives venetoclax/obinutuzumab — Bhavana (Tina) Bhatnagar, DO (22:10) Case: A woman in her early 80s with IGHV-mutated CLL begins treatment with zanubrutinib and 6 months later develops altered mental status due to cryptococcal meningitis — Erik Rupard, MD (33:00) Case: A woman in her early 80s with relapsed CLL (del[17p]/TP53 mutation) develops Stevens-Johnson syndrome while receiving ibrutinib — Spencer H Bachow, MD (38:21) Case: A man in his mid 90s with del(13q) CLL under observation for 12 years begins treatment with zanubrutinib and develops significant bruising/ecchymosis — Dr Rupard (41:14) Case: A woman in her late 70s with relapsed del(13q) CLL receives acalabrutinib and develops hyperleukocytosis — Dr Bhatnagar (45:44) Case: A woman in her mid 80s with rising white blood cell counts and asymptomatic recurrence of CLL (trisomy 12) receives rituximab with subsequent addition of venetoclax — Dr Brenner (50:20) Transformed CLL; CAR T-Cell Therapy (53:38) Journal Club with Dr Davids (54:26) CME information and select publications
Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPCLL24/Part1).
Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia.
In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:Contemporary treatment paradigms for patients with CLLSafety and efficacy of current regimensMolecular testing, including when and how to test for BTK inhibitor resistanceConsidering BTK inhibitor resistance when sequencing therapy Program faculty:Matthew S. Davids, MD, MMScAssociate Professor of MedicineHarvard Medical SchoolLeader, Lymphoma ProgramDana-Farber/Harvard Cancer CenterDirector of Clinical ResearchDivision of LymphomaDana-Farber Cancer InstituteBoston, MassachusettsLindsey Roeker, MDAssistant AttendingCLL Program DirectorDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkResources:To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.
Featuring perspectives from Dr Farrukh T Awan, Dr Matthew S Davids, Dr Stephen J Schuster, Dr William G Wierda and Dr Jennifer Woyach, including the following topics: • Introduction (0:00) • Front-Line Treatment for Chronic Lymphocytic Leukemia (CLL) — Dr Wierda (6:02) • Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors in the Treatment of CLL — Dr Davids (32:37) • Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Awan (53:35) • Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Woyach (1:15:49) • Promising Investigational Agents and Strategies — Dr Schuster (1:37:53) CME information and select publications
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.
In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLLBRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor)BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator's choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCLBRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCLPresenters: Julie M. Vose, MD, MBAChief, Division of Oncology and HematologyNeumann M. and Mildred E. Harris ProfessorDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaMatthew S. Davids, MD, MMScAssociate Professor of MedicineHarvard Medical SchoolDirector of Clinical ResearchDivision of LymphomaDana-Farber Cancer InstituteBoston, MassachusettsLink to full program:https://bit.ly/3OQ6634
In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?What is the optimal therapy for a patient with del(17p) CLL?When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?What are best practices in the use of BTK inhibitors for patients with MCL?How can BTK inhibitor resistance occur?How might investigational noncovalent BTK inhibitors be used should they be approved?What are key adverse events with BTK inhibitors?Presenters:Jeff P. Sharman, MD (chair)Medical DirectorHematology ResearchUS Oncology Willamette Valley Cancer InstituteEugene, Oregon Matthew S. Davids, MD, MMScAssociate Professor of MedicineHarvard Medical SchoolDirector of Clinical ResearchDivision of LymphomaDana-Farber Cancer InstituteBoston, MassachusettsAnthony Mato, MD, MSCEAssociate ProfessorDivision of LeukemiaMemorial Sloan Kettering Cancer CenterNew York, New YorkContent based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5. Link to full program:https://bit.ly/3NEpsYQ
Go online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel explores important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. Upon completion of this accredited CE activity, participants should be better able to: Identify relevant prognostic factors, genetic/molecular findings, and patient- or disease-related features that influence modern treatment selection in chronic lymphocytic leukemia (CLL), Summarize updated efficacy and safety findings surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, or BCL-2 inhibitors; novel combinations; and strategies producing minimal residual disease–negative responses, Select optimized treatment with targeted agents, including fixed duration or continuous therapy, or appropriate combinational or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel explores important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. Upon completion of this accredited CE activity, participants should be better able to: Identify relevant prognostic factors, genetic/molecular findings, and patient- or disease-related features that influence modern treatment selection in chronic lymphocytic leukemia (CLL), Summarize updated efficacy and safety findings surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, or BCL-2 inhibitors; novel combinations; and strategies producing minimal residual disease–negative responses, Select optimized treatment with targeted agents, including fixed duration or continuous therapy, or appropriate combinational or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel explores important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. Upon completion of this accredited CE activity, participants should be better able to: Identify relevant prognostic factors, genetic/molecular findings, and patient- or disease-related features that influence modern treatment selection in chronic lymphocytic leukemia (CLL), Summarize updated efficacy and safety findings surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, or BCL-2 inhibitors; novel combinations; and strategies producing minimal residual disease–negative responses, Select optimized treatment with targeted agents, including fixed duration or continuous therapy, or appropriate combinational or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel explores important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. Upon completion of this accredited CE activity, participants should be better able to: Identify relevant prognostic factors, genetic/molecular findings, and patient- or disease-related features that influence modern treatment selection in chronic lymphocytic leukemia (CLL), Summarize updated efficacy and safety findings surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, or BCL-2 inhibitors; novel combinations; and strategies producing minimal residual disease–negative responses, Select optimized treatment with targeted agents, including fixed duration or continuous therapy, or appropriate combinational or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel explores important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. Upon completion of this accredited CE activity, participants should be better able to: Identify relevant prognostic factors, genetic/molecular findings, and patient- or disease-related features that influence modern treatment selection in chronic lymphocytic leukemia (CLL), Summarize updated efficacy and safety findings surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, or BCL-2 inhibitors; novel combinations; and strategies producing minimal residual disease–negative responses, Select optimized treatment with targeted agents, including fixed duration or continuous therapy, or appropriate combinational or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel explores important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. Upon completion of this accredited CE activity, participants should be better able to: Identify relevant prognostic factors, genetic/molecular findings, and patient- or disease-related features that influence modern treatment selection in chronic lymphocytic leukemia (CLL), Summarize updated efficacy and safety findings surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, or BCL-2 inhibitors; novel combinations; and strategies producing minimal residual disease–negative responses, Select optimized treatment with targeted agents, including fixed duration or continuous therapy, or appropriate combinational or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Guest: Matthew S. Davids, MD, MMSc Guest: Andrew Souers, PhD Apoptosis is a normal and highly regulated process that the body uses to dispose of aged or damaged cells. But what happens when this critical cellular process becomes impaired? Together, Drs. Andy Souers and Matt Davids answer that question and more, like how the protein BCL-2 regulates apoptosis and how venetoclax binds and inhibits BCL-2.
Guest: Matthew S. Davids, MD, MMSc In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts. ABBV-US-00196-MCVersion 1.0, Approved August 2020
Guest: Matthew S. Davids, MD, MMSc In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts. ABBV-US-00196-MCVersion 1.0, Approved August 2020
Guest: Matthew S. Davids, MD, MMSc In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts. ABBV-US-00196-MCVersion 1.0, Approved August 2020
Guest: Matthew S. Davids, MD, MMSc In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts. ABBV-US-00196-MCVersion 1.0, Approved August 2020
© 2020-2025 Ivy Podcast Discovery LLC
